The original disclosure in Japanese was released on August 4, 2020 at 15:00 (GMT+8)

Consolidated Financial Statements for the First Quarter Ended June 30, 2020
FY2021 (April 1, 2020 - June 30, 2020) [UNAUDITED]
August 4, 2020
Takara Bio Inc.
Tokyo Stock Exchange (1st section)4974
http://www.takara-bio.co.jp
Koichi Nakao, President
Takuya Kakemi, General Manager of Corporate
Management Division, Executive Officer
Tel. (077) 565-6970
August 12, 2020

Company name:
Stock exchange listings:
Code number:
URL:
Company representative:
Contact:

Scheduled date of quarterly statement filing:
Scheduled date of starting delivery of dividends:－Supplementary documents of the financial results:
Yes
Financial results information meeting:
NoNotes: 1. The accompanying financial statements have been prepared in accordance with accounting principles andpractices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.
1. Results for the three months ended June 30, 2020 (Apr. 1, 2020 – Jun. 30, 2020)(1) Consolidated operating results(Percentages indicate changes from the same period of the previous fiscal year.)Three months ended
Jun. 30, 2020

Net sales
Operating profit
Ordinary profit
Net income (loss) attributable to owners ofparent
Net income per share (in yen)
Fully diluted net income per share (in yen)
(Note) Comprehensive income(2) Consolidated financial position
Total assets
Net assets
Equity ratio (%)
Net assets per share (in yen)
(Reference) Equity
2. Dividends
Year ended
Mar. 31, 2020

(Millions of yen)
6,938
693
745
404
3.36－(48)(%)

Three months ended
Jun. 30, 2019

(Millions of yen)
8,650
2,251
2,200
1,591(2.2)
45.8
41.1
54.2

(－%)

13.22－1,778(－%)

As of Jun. 30, 2020
(Millions of yen)

As of Mar. 31, 2020
(Millions of yen)

73,59365,58089.0543.82
65,48475,00966,591
88.7
552.2366,496

Annual dividends per share in yen
Year ending
Mar. 31, 2021

－
－
0.00
－
8.00
8.00
Note: No revision of dividend payment forecast since the most recently announced payment forecast.

First quarter end
Second quarter end
Third quarter end
Year end
Annual(%)(19.8)(69.2)(66.1)(74.6)

Year ending
Mar. 31, 2021 (Forecast)
0.00
－
8.00
8.00

The original disclosure in Japanese was released on August 4, 2020 at 15:00 (GMT+8)
3. Forecast for the year ending March 31, 2021 (Apr. 1, 2020 – Mar. 31, 2021)(Percentages indicated changes from the same period of the previous fiscal year)

Six months ending
Sep. 30, 2020
Net sales
Operating profit
Ordinary profit
Net income attributable toowners of the parent
Net income per share(in yen)(Millions yen)
16,870
2,500
2,559
1,248

Year ending
Mar. 31, 2021(%)
2.6
(17.6)(13.6)(39.8)(Millions yen)
39,600
6,500
6,600
4,000

10.37

(%)
14.63.6
4.0
4.7

33.22

Note: Revision of financial forecast since the most recently announced payment forecast: Yes.

※ Others(1) Changes in subsidiaries during the three months ended June 30, 2020
(Changes in specified subsidiaries resulting in change of scope)： No
Newly included: － (Name)
Excluded: － (Name)(2) Application of special accounting methods to the consolidated quarterly financial statements： No(3) Changes in accounting policies, changes in accounting estimates, and retrospective restatement
1) Changes based on revisions of accounting standard： No2) Changes other than ones based on revisions of accounting standard： No
3) Changes in accounting estimates： No4) Restatement： No(4) Number of outstanding shares (Common stock)1) Number of outstanding shares at year end (Treasury stocks are included)
120,415,600
As of June 30, 2020
As of March 31, 2020
120,415,600
2) Number of treasury stocks at year end－
As of June 30, 2020－
As of March 31, 2020
3) Average number of outstanding shares
120,415,600
As of June 30, 2020
120,415,600
As of June 30, 2019
※ These quarterly financial statements are not subject to auditing.
※ Comment regarding appropriate use of earnings forecasts and other special notes
Forward-looking statements contained in this document are determined by the Takara Bio Company based on information
currently available to the Company and include a number of uncertainties. Actual results could differ from these forecasts due tochanges in conditions that occur in the future. For information regarding the above, please refer to 1. Qualitative Information for
the three months ended June 30, 2020 (4) Qualitative Information Regarding Consolidated Forecasts on page 2 of the attacheddocument.